BeiGene
BGNE
#881
Rank
NZ$38.49 B
Marketcap
$344.02
Share price
-0.65%
Change (1 day)
1.71%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total liabilities

Total liabilities on the balance sheet as of June 2024 : NZ$3.92 Billion

According to BeiGene 's latest financial reports the company's total liabilities are NZ$3.92 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BeiGene - Total liabilities on balance sheet (from 2014 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31NZ$3.58 B14.08%
2022-12-31NZ$3.14 B-10.64%
2021-12-31NZ$3.51 B46.6%
2020-12-31NZ$2.39 B154.94%
2019-12-31NZ$0.94 B27.29%
2018-12-31NZ$0.73 B44.98%
2017-12-31NZ$0.51 B567.82%
2016-12-31NZ$76.37 M23.16%
2015-12-31NZ$62.01 M74.45%
2014-12-31NZ$35.54 M-42.18%
2013-12-31NZ$61.48 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
NZ$20.35 M-99.48%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.97 B-75.08%๐Ÿ‡บ๐Ÿ‡ธ USA